Trial Profile
Retrospective observational chart review investigating the safety and efficacy of rivaroxaban in the treatment of cancer-associated thrombosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cancer; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology